PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer / Lin, Chang-Ching; Chang, Tsung-Cheng; Wang, Yunguan; Guo, Lei; Gao, Yunpeng; Bikorimana, Emmanuel; Lemoff, Andrew; Fang, Yisheng V.; Zhang, He; Zhang, Yanfeng; Ye, Dan; Soria-Bretones, Isabel; Servetto, Alberto; Lee, Kyung-min; Luo, Xuemei; Otto, Joseph J.; Akamatsu, Hiroaki; Napolitano, Fabiana; Mani, Ram; Cescon, David W.; Xu, Lin; Xie, Yang; Mendell, Joshua T.; Hanker, Ariella B.; Arteaga, Carlos L.. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 15:1(2024). [10.1038/s41467-024-46495-2]

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Servetto, Alberto;Napolitano, Fabiana;
2024

2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer / Lin, Chang-Ching; Chang, Tsung-Cheng; Wang, Yunguan; Guo, Lei; Gao, Yunpeng; Bikorimana, Emmanuel; Lemoff, Andrew; Fang, Yisheng V.; Zhang, He; Zhang, Yanfeng; Ye, Dan; Soria-Bretones, Isabel; Servetto, Alberto; Lee, Kyung-min; Luo, Xuemei; Otto, Joseph J.; Akamatsu, Hiroaki; Napolitano, Fabiana; Mani, Ram; Cescon, David W.; Xu, Lin; Xie, Yang; Mendell, Joshua T.; Hanker, Ariella B.; Arteaga, Carlos L.. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 15:1(2024). [10.1038/s41467-024-46495-2]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/981532
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact